on December 12, 2002
Published online before print December 12, 2002, doi: 10.1161/01.STR.0000046458.67968.E4
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 22, 2002
From the Division of Critical Care Neurology, Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons, New York, NY. * To whom correspondence should be addressed. E-mail: sam14{at}columbia.edu.
Background—Intracerebral hemorrhage (ICH) causes higher morbidity and mortality than other forms of stroke and has no proven effective treatment. Hematoma volume is a powerful predictor of outcome after ICH. Summary of Review—Historically, ICH bleeding was considered to be a monophasic event that stopped quickly as a result of clotting and tamponade by surrounding brain tissue. More recently, prospective and retrospective CT-based studies have demonstrated that hematoma growth occurs in up to 38% of patients initially scanned within 3 hours of onset and in 16% scanned between 3 and 6 hours, even in the absence of coagulopathy. Progressive bleeding of this type has been associated with contrast extravasation on CT angiography and poor outcome after early (<4 hours) surgical clot evacuation. On the basis of these observations, it is plausible that ultra-early hemostatic therapy given in the emergency setting might reduce ICH volume in some patients and improve outcome. Among candidate agents for this indication, the most promising is recombinant activated factor VIIa, which promotes local hemostasis at sites of vascular injury in both coagulopathic and normal patients. Conclusions—Ultra-early hemostatic therapy, given within 3 to 4 hours of onset, may potentially arrest ongoing bleeding and minimize hematoma growth after ICH. Given the current lack of effective therapy for ICH, clinical trials testing this treatment approach are justified.
Accepted on August 2, 2002
Ultra-Early Hemostatic Therapy for Intracerebral Hemorrhage
Stephan A. Mayer MD*
Key words: cerebral hemorrhage • factor VIIa • hemostasis • stroke management
This article has been cited by other articles:
 |
|
 |
|
  D. F. Hanley Intraventricular Hemorrhage: Severity Factor and Treatment Target in Spontaneous Intracerebral Hemorrhage Stroke, April 1, 2009; 40(4): 1533 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mayer, S. M. Davis, B. E. Skolnick, N. C. Brun, K. Begtrup, J. P. Broderick, M. N. Diringer, and T. Steiner Can a Subset of Intracerebral Hemorrhage Patients Benefit From Hemostatic Therapy With Recombinant Activated Factor VII? Stroke, March 1, 2009; 40(3): 833 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Flaherty, H. Tao, M. Haverbusch, P. Sekar, D. Kleindorfer, B. Kissela, P. Khatri, B. Stettler, O. Adeoye, C. J. Moomaw, et al. Warfarin use leads to larger intracerebral hematomas Neurology, September 30, 2008; 71(14): 1084 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Mayer, N. C. Brun, K. Begtrup, J. Broderick, S. Davis, M. N. Diringer, B. E. Skolnick, T. Steiner, and the FAST Trial Investigators Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage N. Engl. J. Med., May 15, 2008; 358(20): 2127 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Goldstein, L. E. Fazen, R. Snider, K. Schwab, S. M. Greenberg, E. E. Smith, M. H. Lev, and J. Rosand Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage Neurology, March 20, 2007; 68(12): 889 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mayer Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage Stroke, February 1, 2007; 38(2): 763 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Webster III, J. S. Kim, N. J. Cowan, G. S. Chirikjian, and A. M. Okamura Nonholonomic Modeling of Needle Steering The International Journal of Robotics Research, May 1, 2006; 25(5-6): 509 - 525. [Abstract] [PDF]
|
|
|
|
|
|
S. M. Davis, J. Broderick, M. Hennerici, N. C. Brun, M. N. Diringer, S. A. Mayer, K. Begtrup, T. Steiner, and for the Recombinant Activated Factor VII Intracere Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage Neurology, April 25, 2006; 66(8): 1175 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Godoy, G. Pinero, and M. Di Napoli Predicting Mortality in Spontaneous Intracerebral Hemorrhage: Can Modification to Original Score Improve the Prediction? Stroke, April 1, 2006; 37(4): 1038 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Gerber, S. A. Grossman, and M. B. Streiff Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors J. Clin. Oncol., March 10, 2006; 24(8): 1310 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Foerch, I Curdt, B Yan, F Dvorak, M Hermans, J Berkefeld, A Raabe, T Neumann-Haefelin, H Steinmetz, and M Sitzer Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 181 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Steiner, J. Rosand, and M. Diringer Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy: Current Practices and Unresolved Questions Stroke, January 1, 2006; 37(1): 256 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Manno, J. L. D. Atkinson, J. R. Fulgham, and E. F. M. Wijdicks Emerging Medical and Surgical Management Strategies in the Evaluation and Treatment of Intracerebral Hemorrhage Mayo Clin. Proc., March 1, 2005; 80(3): 420 - 433. [Abstract] [PDF]
|
|
|
|
|
|
NINDS ICH Workshop Participants Priorities for Clinical Research in Intracerebral Hemorrhage: Report From a National Institute of Neurological Disorders and Stroke Workshop Stroke, March 1, 2005; 36(3): e23 - e41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mayer, N. C. Brun, K. Begtrup, J. Broderick, S. Davis, M. N. Diringer, B. E. Skolnick, T. Steiner, and the Recombinant Activated Factor VII Intracerebral Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage N. Engl. J. Med., February 24, 2005; 352(8): 777 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Davalos and M. Fisher Emerging Therapies for Cerebrovascular Disorders Stroke, February 1, 2005; 36(2): 208 - 210. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mayer, N. C. Brun, J. Broderick, S. Davis, M. N. Diringer, B. E. Skolnick, T. Steiner, and for the Europe/AustralAsia NovoSeven ICH Trial Inv Safety and Feasibility of Recombinant Factor VIIa for Acute Intracerebral Hemorrhage Stroke, January 1, 2005; 36(1): 74 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Roberts, D. M. Monroe, and G. C. White The use of recombinant factor VIIa in the treatment of bleeding disorders Blood, December 15, 2004; 104(13): 3858 - 3864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Flibotte, N. Hagan, J. O'Donnell, S. M. Greenberg, and J. Rosand Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage Neurology, September 28, 2004; 63(6): 1059 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Leira, A. Davalos, Y. Silva, A. Gil-Peralta, J. Tejada, M. Garcia, and J. Castillo Early neurologic deterioration in intracerebral hemorrhage: Predictors and associated factors Neurology, August 10, 2004; 63(3): 461 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hanley and W. Hacke Critical Care and Emergency Medicine Neurology Stroke, February 1, 2004; 35(2): 365 - 366. [Full Text] [PDF]
|
|
|
|
|
|
E.-C. Song, K. Chu, S.-W. Jeong, K.-H. Jung, S.-H. Kim, M. Kim, and B.-W. Yoon Hyperglycemia Exacerbates Brain Edema and Perihematomal Cell Death After Intracerebral Hemorrhage Stroke, September 1, 2003; 34(9): 2215 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Maurino Hypothesis of Intracerebral Hemorrhage Growth Stroke, July 1, 2003; 34 (7): e78 - e78. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Donnan and S. M. Davis Surgery for Intracerebral Hemorrhage: An Evidence-Poor Zone Stroke, June 1, 2003; 34(6): 1569 - 1570. [Full Text] [PDF]
|
|